Ananda Pharma PLC (ANA) ORD GBP0.002

Ananda Pharma plc, formerly Ananda Developments plc, is a United Kingdom-based pharmaceutical company. The Company is focused on the research and development of cannabidiol (CBD)-based therapies. It is engaged in developing medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with chemotherapy induced peripheral neuropathy (CIPN) & endometriosis) and Heart Failure with preserved Ejection Fraction (HFpEF). ACTiON is a Phase II, double blind placebo-controlled crossover randomized clinical trial (RCT) to assess its MRX1 drug candidate versus placebo in the treatment of CIPN. ENDOCAN-1 shall help determining whether a cannabinoid can reduce endometriosis-associated pain. HFpEF is a study designed to evaluate the cardioprotective effects of its MRX1 drug candidate in a preclinical HFpEF model. Its two novel cannabinoid medicines: MRX2 (CBD) and MRX2T, helps in a range of seizure types and epilepsies in children and adults.